Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.

Rhyter Times aggregates short excerpts. The full story is reported by Biopharma dive.

Read the full story at Biopharma dive →